Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

Abstract

These findings suggest that anakinra appears to be effective in treating pediatric patients with non-malignancy-associated secondary HLH/MAS, especially when it is given early in the disease course and when administered to patients who have an underlying rheumatic disease.